Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study. Rahbar K, Schlack K, Bogemann M. BMC Cancer 2025;25:1159.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rahbar K, Schlack K, Bogemann M. Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study. BMC Cancer 2025;25:1159.
PMID: 40640763